Entities / Company
Merck KGaA.
German multinational science and technology company
- Reports this week
- 3
- Active events
- 3
- Connections
- 660
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Keytruda received FDA approval for cancer treatment, involving Merck KGaA.Well supported4 reports
-
Merck KGaA acquired Schering-Plough in 2009.Some support1 report
-
Merck KGaA stock saw activity as an EVP sold shares, while Mirae Asset increased its stake, alongside Norges Bank's previous acquisition.Some support2 reports
Earlier this month
-
Merck KGaA and the Church of the Brethren collaborate with several companies, including Integra LifeSciences and Henry Schein, to contribute to a new facility stock.Some support1 report
-
Bioinvent presented data combining its BI-1808 therapy with MSD's KEYTRUDA® at the ESMO Congress in Madrid.Some support1 report
-
Oncolytics Biotech and Merck KGaA signed a co-development agreement for the immunotherapy candidate pelareorep.Some support1 report
-
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Well supported21 reports10 developments inside
-
Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.Some support5 reports
-
Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.Some support1 report
-
Merck KGaA and ABVC BioPharma are competing for investment as healthcare companies.Some support1 report
-
Morgan Stanley reduced its price target on Merck KGaA while Manufacturers Life Insurance Company increased its holdings in the stock.Some support1 report
One to three months ago
-
Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.Well supported3 reports1 development inside
-
MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Some support1 report
-
Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Some support5 reports
-
A combination drug from Merck KGaA and Inhibrx Biosciences showed a higher response rate, leading to a stock price drop reported by Reuters.Some support1 report
-
Merck KGaA announced a definitive agreement to acquire Bio-Techne.Well supported6 reports
-
Merck KGaA is the subject of analyst rating upgrades from HSBC and Scotiabank, alongside increased stock holdings by Geode Capital Management and related SEC filings.Some support1 report
-
Merck KGaA won an award for sustainable innovation.Some support1 report
-
Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.Some support2 reports1 development inside
-
Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.Some support3 reports
-
Merck KGaA and AstraZeneca's drug pipelines are facing market competition, with J.P. Morgan reiterating an Overweight rating.Some support1 report
-
Robert Plenge holds various appointments, including Chief Research Officer at Bristol-Myers Squibb, and serves on the boards of BioMarin Pharmaceutical and the PhRMA Foundation.Some support1 report
-
Multiple financial institutions, including Norges Bank, Morgan Stanley, and Geode Capital Management, adjusted their holdings in Merck KGaA shares.Some support3 reports
-
Merck KGaA's headquarters are located in Darmstadt, Germany.Some support1 report1 development inside
-
Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.Some support1 report
-
Merck KGaA operates as a science and technology company in Germany.Well supported13 reports1 development inside
-
Norges Bank acquired a new stake in Merck KGaA worth $3.9 billion, filing the required Form 13F with the SEC.Some support4 reports1 development inside
-
MarketBeat is reporting on the company performance of Merck KGaA, a science company based in Germany.Some support2 reports
-
Aspen Pharmacare gained rights to manufacture medicines with Merck/MSD to improve access to pharmaceuticals in Africa.Some support2 reports2 developments inside
Gone quiet
No new reports in 90+ days-
Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.Some support2 reports2 developments inside
-
Pfizer and Merck KGaA are navigating market pressures as the COVID franchise revenue streams decline.Some support1 report
-
Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.Some support1 report
-
A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.Some support1 report1 development inside
-
Merck KGaA filed required documentation with the Securities and Exchange Commission regarding public company oversight.Well supported10 reports1 development inside
-
Morgan Stanley boosted its position in Merck KGaA, while Geode Capital Management lifted its holdings in the company.Some support1 report
-
Merck KGaA received a reaffirmed neutral rating, reduced its stake by 18.5%, and filed 13F reports with the SEC.Some support1 report
-
Litigation in Europe and ongoing FDA review are impacting the market viability and stock performance of Merck KGaA and SamChunDang Pharm.Some support1 report
-
An analyst report was released on July 4, 2026, leading to a target price increase for Merck KGaA.Well supported7 reports
-
Merck KGaA and Eli Lilly and Company experienced stock declines on July 20, 2026, amid market sentiment shifts.Some support1 report
-
Merck KGaA and Physiomics plc are providing modeling and data science services.Some support1 report
-
Institutional investors, including Sumitomo Mitsui Trust Holdings, Inc., decreased their holdings in Merck KGaA by 10.1% in Q1 2026.Some support1 report
-
Multiple financial firms, including Citigroup, Bank of America, and Cantor Fitzgerald, issued rating updates on Merck KGaA shares.Some support8 reports
-
Glocer has been appointed to the board of directors at both Merck KGaA and Morgan Stanley.Some support2 reports
-
Merck KGaA received analyst coverage and increased institutional stake in its stock from various firms.Some support1 report1 development inside
-
Jefferies Financial Group started coverage on Merck KGaA shares.Some support1 report
-
Roy Vagelos, co-founder of Regeneron, has joined Merck KGaA, rising from R&D to COO.Some support1 report
-
Merck KGaA agreed to acquire Bio-Techne, while an analyst boosted the price target for Avantor stock.Some support1 report
-
Merck KGaA announced a new CEO who previously gained experience at the company.Some support1 report
-
Merck KGaA and Hoffmann-La Roche are seeking FDA approval for combination treatments and expanding pneumococcal vaccine labels.Some support1 report
-
Morgan Stanley bought shares of Merck KGaA on June 16, 2026.Some support1 report
-
Merck KGaA has acquired Terns Pharmaceuticals in a deal valued at $6.7 billion.Some support1 report
-
Geode Capital Management increased its stake in Merck KGaA by 0.4%, purchasing a new stake valued at approximately $3.99 billion.Some support2 reports
-
The FDA is currently evaluating data needed for alternate dosing licenses, while sales in China declined significantly in 2025.Speculative2 reports
-
Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.Some support3 reports
-
The market is currently dominated by key players, including Merck & Co., Amgen, and Moderna.Speculative1 report
-
Jefferies maintained a Buy rating on Merck & Co., citing revenue growth from Keytruda and vaccine sales stability.Speculative1 report
-
Merck acquired Verona Pharma for $10 billion on August 5, 2025.Well supported11 reports
-
Merck & Co. and Verona Pharma are diversifying operations and expanding global clinical trial access ahead of the KEYTRUDA patent expiry.Some support1 report
-
Merck & Co. is based in Kenilworth, NJ.Some support1 report
-
Merck & Co. and Shearwell Data are key players in the livestock identification market.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Merck KGaA this week
News at the entities that move Merck KGaA most-
Moderna OperationalScottish Mortgage Investment Trust, managed by Baillie Gifford, highlighted its key holdings in SpaceX and Moderna.Moves Merck KGaA
-
FDA OperationalThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves Merck KGaA
-
Norges Bank TransactionalNorges Bank, BNP Paribas, Morgan Stanley, and Benchmark made various investment moves regarding Datadog shares on June 15, 2026.Moves Merck KGaA
-
Eli Lilly and Company OperationalTrade data and legislative control are currently influencing market sentiment and corporate operations.Moves Merck KGaA
-
Securities and Exchange Commission StructuralStar Holdings sold a land parcel in Coney Island and filed its quarterly report with the SEC.Moves Merck KGaA
-
Morgan Stanley StructuralSurrozen utilized conference platforms hosted by Morgan Stanley in South San Francisco on September 1, 2026.Moves Merck KGaA
Connections
The 40 strongest of 660, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
E. Merck Structural
Merck KGaA's related entity was established as a subsidiary of E. Merck.
-
Bio-Techne Transactional
Merck KGaA is acquiring Bio-Techne through a definitive shareholder sale agreement.
-
MSD Structural
MSD is a subsidiary of Merck & Co., Inc., with the name varying based on geographic market.
-
Moderna Operational
Merck KGaA and Moderna maintain a strategic partnership focused on jointly developing and testing personalized mRNA cancer vaccines.
-
Securities and Exchange Commission Structural
Merck KGaA operates under the formal regulatory oversight of the SEC, requiring mandatory institutional holdings reports (Form 13F).
-
Dean Y. Li Structural
Dean Y. Li serves in an executive capacity at Merck Research Laboratories.
-
FDA Operational
The FDA evaluates and approves pharmaceutical products submitted by Merck KGaA, granting market access based on rigorous review processes.
-
Norges Bank Transactional
Norges Bank acquired a new stake in Merck KGaA valued at approximately $3.9 billion.
Show all 40 connections
-
Morgan Stanley Structural
The relationship is structural, maintained through shared board representation and continuous active investment and rating coverage by Morgan Stanley.
-
Eli Lilly and Company Operational
The two pharmaceutical companies are direct competitors in the advanced drug development market.
-
Merck Animal Health Structural
Merck Animal Health operates as a dedicated division of the larger entity, Merck KGaA.
-
Royal Bank of Canada Operational
Royal Bank of Canada provides financial ratings and research notes on Merck KGaA stock.
-
Oncolytics Biotech Operational
Oncolytics Biotech and Merck KGaA are engaged in a co-development agreement for the drug pelareorep.
-
Pfizer Operational
The companies actively compete in various therapeutic markets, collaborate on specific product approvals, and have engaged in corporate transactions.
-
SEC Structural
Merck KGaA is subject to mandatory institutional holdings and investment activity disclosure requirements enforced by the SEC.
-
Schering-Plough Structural
Merck KGaA acquired Schering-Plough in 2009, establishing a parent-subsidiary relationship.
-
China Structural
Merck KGaA conducts business operations, including product sourcing and sales, within the Chinese market.
-
Veeva Systems Structural
Veeva provides specialized Agentic CRM and AI tools essential for Merck KGaA's ongoing operational functions.
-
Belén Garijo Structural
Belén Garijo holds the position of CEO at Merck KGaA.
-
Kenneth Frazier Transactional
A served as the leader of B, a role held until 2021.
-
Ligand Pharmaceuticals Operational
Ligand Pharmaceuticals and Merck KGaA maintain ongoing partnerships and alliances for drug development.
-
HSBC Mentioned together
HSBC provides financial research reports and target price analysis on Merck KGaA stock.
-
Bioinvent Operational
Bioinvent is actively studying and combining its therapies with Merck KGaA's anti-PD-1 and KEYTRUDA® therapies.
-
Bank of America Mentioned together
Bank of America provides financial analysis, raising price targets and issuing buy ratings for Merck KGaA.
-
Gilead Sciences Operational
The two companies are current competitors in the fragmented HIV drug market and share a history of collaboration.
-
Leerink partners Mentioned together
Leerink partners provides financial coverage, consistently raising price targets and ratings for Merck KGaA.
-
Hilltop Holdings Inc. Transactional
Merck KGaA reduced its investment stake in Hilltop Holdings Inc. by 18.5% during Q1.
-
AstraZeneca Operational
The two companies actively compete against each other within the global pharmaceutical market.
-
Daiwa Securities Operational
The relationship is characterized by market coverage and analyst influence, where upgrades impact market sentiment.
-
MarketBeat Mentioned together
MarketBeat tracks, aggregates, and reports on the financial performance and stock status of Merck KGaA.
-
Danaher Corporation Operational
The two companies are active competitors operating within the diagnostic market space.
-
Geode Capital Management Transactional
Geode Capital Management is divesting its stake in Merck KGaA following an initial increase during the fourth quarter of 2026.
-
Severino Structural
Severino held a past executive position within Merck KGaA.
-
AbbVie Operational
AbbVie and Merck KGaA are major pharmaceutical companies that actively compete in the development and sales of pharmaceuticals.
-
Scotiabank Mentioned together
Scotiabank provides financial analysis and price target updates regarding Merck KGaA stock.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides financial ratings and price targets for Merck KGaA in research notes.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides analyst coverage and ratings for Merck KGaA shares.
-
Citigroup Mentioned together
The relationship is based on co-mention in financial media, specifically through shared analyst coverage and ratings.
-
Manufacturers Life Insurance Company Transactional
Manufacturers Life Insurance Company increased its investment holdings in Merck KGaA stock.
-
Church of the Brethren Operational
Merck KGaA and the Church of the Brethren maintain a collaborative partnership.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
6 events- Merck KGaA and the Church of the Brethren collaborate with several companies, including Integra LifeSciences and Henry Schein, to contribute to a new facility stock.
- Bioinvent presented data combining its BI-1808 therapy with MSD's KEYTRUDA® at the ESMO Congress in Madrid.
- Oncolytics Biotech and Merck KGaA signed a co-development agreement for the immunotherapy candidate pelareorep.
- Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.
- Merck KGaA and ABVC BioPharma are competing for investment as healthcare companies.
- Morgan Stanley reduced its price target on Merck KGaA while Manufacturers Life Insurance Company increased its holdings in the stock.
September 2026
9 events- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.
- A combination drug from Merck KGaA and Inhibrx Biosciences showed a higher response rate, leading to a stock price drop reported by Reuters.
- Merck KGaA is the subject of analyst rating upgrades from HSBC and Scotiabank, alongside increased stock holdings by Geode Capital Management and related SEC filings.
- Merck KGaA won an award for sustainable innovation.
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.
- Merck KGaA and AstraZeneca's drug pipelines are facing market competition, with J.P. Morgan reiterating an Overweight rating.
- Robert Plenge holds various appointments, including Chief Research Officer at Bristol-Myers Squibb, and serves on the boards of BioMarin Pharmaceutical and the PhRMA Foundation.
- Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.
Show 3 earlier months
August 2026
7 events- Merck KGaA stock saw activity as an EVP sold shares, while Mirae Asset increased its stake, alongside Norges Bank's previous acquisition.
- Multiple financial institutions, including Norges Bank, Morgan Stanley, and Geode Capital Management, adjusted their holdings in Merck KGaA shares.
- Merck KGaA's headquarters are located in Darmstadt, Germany.
- Norges Bank acquired a new stake in Merck KGaA worth $3.9 billion, filing the required Form 13F with the SEC.
- MarketBeat is reporting on the company performance of Merck KGaA, a science company based in Germany.
- Pfizer and Merck KGaA are navigating market pressures as the COVID franchise revenue streams decline.
- Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.
July 2026
10 events- Aspen Pharmacare gained rights to manufacture medicines with Merck/MSD to improve access to pharmaceuticals in Africa.
- A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.
- Morgan Stanley boosted its position in Merck KGaA, while Geode Capital Management lifted its holdings in the company.
- Merck KGaA received a reaffirmed neutral rating, reduced its stake by 18.5%, and filed 13F reports with the SEC.
- Litigation in Europe and ongoing FDA review are impacting the market viability and stock performance of Merck KGaA and SamChunDang Pharm.
- An analyst report was released on July 4, 2026, leading to a target price increase for Merck KGaA.
- Merck KGaA and Eli Lilly and Company experienced stock declines on July 20, 2026, amid market sentiment shifts.
- Merck KGaA and Physiomics plc are providing modeling and data science services.
- Institutional investors, including Sumitomo Mitsui Trust Holdings, Inc., decreased their holdings in Merck KGaA by 10.1% in Q1 2026.
- Multiple financial firms, including Citigroup, Bank of America, and Cantor Fitzgerald, issued rating updates on Merck KGaA shares.
June 2026
27 events- Keytruda received FDA approval for cancer treatment, involving Merck KGaA.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.
- Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.
- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.
- Merck KGaA announced a definitive agreement to acquire Bio-Techne.
- Merck KGaA operates as a science and technology company in Germany.
- Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.
- Merck KGaA filed required documentation with the Securities and Exchange Commission regarding public company oversight.
- Glocer has been appointed to the board of directors at both Merck KGaA and Morgan Stanley.
- Merck KGaA received analyst coverage and increased institutional stake in its stock from various firms.
- Jefferies Financial Group started coverage on Merck KGaA shares.
- Roy Vagelos, co-founder of Regeneron, has joined Merck KGaA, rising from R&D to COO.
- Merck KGaA agreed to acquire Bio-Techne, while an analyst boosted the price target for Avantor stock.
- Merck KGaA announced a new CEO who previously gained experience at the company.
- Merck KGaA and Hoffmann-La Roche are seeking FDA approval for combination treatments and expanding pneumococcal vaccine labels.
- Morgan Stanley bought shares of Merck KGaA on June 16, 2026.
- Merck KGaA has acquired Terns Pharmaceuticals in a deal valued at $6.7 billion.
- Geode Capital Management increased its stake in Merck KGaA by 0.4%, purchasing a new stake valued at approximately $3.99 billion.
- The FDA is currently evaluating data needed for alternate dosing licenses, while sales in China declined significantly in 2025.
- Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.
- The market is currently dominated by key players, including Merck & Co., Amgen, and Moderna.
- Jefferies maintained a Buy rating on Merck & Co., citing revenue growth from Keytruda and vaccine sales stability.
- Merck acquired Verona Pharma for $10 billion on August 5, 2025.
- Merck & Co. and Verona Pharma are diversifying operations and expanding global clinical trial access ahead of the KEYTRUDA patent expiry.
- Merck & Co. is based in Kenilworth, NJ.
- Merck & Co. and Shearwell Data are key players in the livestock identification market.